Former US CEO of Boehringer Ingelheim becomes chairman at Inotek Pharmaceuticals
pharmafile | April 11, 2016 | Appointment | Medical Communications | Boehringer Ingelheim, inotek, inotek pharma, j martin carroll
Inotek Pharmaceuticals has announced the appointment of J. Martin Carroll as the new chairman of the board. Carroll will succeed Argeris Karabelas as chairperson at the 2016 Annual Meeting in June.
Carroll most recently led Global Strategy and Development for Boehringer Ingelheim. He also previously oversaw US revenue in excess of $7 billion and over 10,000 employees when president and CEO of the Boehringer Ingelheim US businesses. He spent 25 years at MSD, most recently as executive vice president of customer marketing and sales. Possessing a BA in accounting and economics and an MBA from Babson College, Carroll is also currently a member of the board of directors of Catalent, TherapeuticsMD and Mallinckrodt Pharmaceuticals.
David P. Southwell, president and chief executive officer of Inotek, comments: “We are excited to have Mr Carroll join Inotek’s board. Over the past year we have named four outstanding executives to our board, and Marty’s experience will significantly complement their expertise. Mr Carroll has a track record of success as a pharmaceutical leader and will bring operational experience in many areas including R&D, manufacturing and sales. His diverse expertise will be invaluable to us as we further develop Inotek into a leading ophthalmology company.”
Carroll says: “I am pleased to join the board of Inotek during an exciting time. The company’s world class leadership team and board of directors demonstrates their commitment to bring novel ocular therapies to market for patients. I look forward to working closely with Inotek’s management and board.”
He joins the pharma company at an important time, as the recent publication of Inotek’s financial results revealed a net loss of $68 million for the year ending December 31 2015.
Related Content
Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis
Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a …
Boehringer Ingelheim acquires Nerio Therapeutics, strengthening immune-oncology profile
Biopharmaceutical company Boehringer Ingelheim has announced the acquisition of drug discovery and development company Nerio …
Brainomix and Boehringer Ingelheim enter strategic partnership
Brainomix has announced that it has entered into a strategic partnership with Boehringer Ingelheim for …
